Advertisement

Topics

Ritter’s RP-G28 mitigates lactose intolerance symptoms in Phase IIb/III trial

19:00 EDT 6 Aug 2017 | Net Resources International

US-based Ritter Pharmaceuticals has reported positive additional results from a Phase IIb/III trial of its product candidate RP-G28 in patients suffering from lactose intolerance (LI).

Original Article: Ritter’s RP-G28 mitigates lactose intolerance symptoms in Phase IIb/III trial

NEXT ARTICLE

More From BioPortfolio on "Ritter’s RP-G28 mitigates lactose intolerance symptoms in Phase IIb/III trial"

Quick Search
Advertisement